160 related articles for article (PubMed ID: 8632489)
1. Antibody-enzyme conjugates for cancer therapy.
Melton RG; Sherwood RF
J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
[TBL] [Abstract][Full Text] [Related]
2. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
Syrigos KN; Epenetos AA
Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606
[TBL] [Abstract][Full Text] [Related]
3. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
4. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
Sharma SK; Bagshawe KD
Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
[TBL] [Abstract][Full Text] [Related]
5. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
6. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
7. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
Senter PD
FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
9. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).
Varner JD
Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273
[TBL] [Abstract][Full Text] [Related]
10. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.
Bagshawe KD; Sharma SK; Begent RH
Expert Opin Biol Ther; 2004 Nov; 4(11):1777-89. PubMed ID: 15500406
[TBL] [Abstract][Full Text] [Related]
11. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
12. ADEPT and related concepts.
Bagshawe KD
Cell Biophys; 1994; 24-25():83-91. PubMed ID: 7736543
[TBL] [Abstract][Full Text] [Related]
13. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
Wallace PM; Senter PD
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
15. A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
Haisma HJ; Van Muijen M; Scheffer G; Scheper RJ; Pinedo HM; Boven E
Hybridoma; 1995 Aug; 14(4):377-82. PubMed ID: 8522350
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
Springer CJ; Poon GK; Sharma SK; Bagshawe KD
Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
[TBL] [Abstract][Full Text] [Related]
17. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Kubizek F; Eggenreich B; Spadiut O
Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
[TBL] [Abstract][Full Text] [Related]
18. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
[TBL] [Abstract][Full Text] [Related]
19. Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine.
Abraham R; Aman N; von Borstel R; Darsley M; Kamireddy B; Kenten J; Morris G; Titmas R
Cell Biophys; 1994; 24-25():127-33. PubMed ID: 7736516
[TBL] [Abstract][Full Text] [Related]
20. Advances in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Begent RH
Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
